ArticleFuture oncology (London, England)2025

CAMBRIA-1 & CAMBRIA-2 phase III trials: camizestrant versus standard endocrine therapy in ER+/HER2- early breast cancer.

Erika P Hamilton et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.